A global biopharmaceutical company has announced it will invest $1.5 billion for a new manufacturing facility in Bradley, but the taxpayer cost of the project is ...

Australian biopharmaceutical company CSL announced Monday a major expansion at its Kankakee manufacturing facility, a move that will bring end-to-end plasma processing into the U.S.

The Melbourne-based company will build a 330,000-square-foot facility and retain 1,200 existing positions. Construction is ...

CSL, a global pharmaceutical manufacturer based in Melbourne, Australia, has broken ground on a $1.5 billion expansion of its campus in Kankakee, roughly 60 miles southwest of Chicago. The company has ...

After teasing a plasma-based manufacturing expansion in the U.S. late last year, CSL is putting in the work and firming up details behind the $1.5-billion project.  | On Monday, CSL broke ground on an ...

The Kanakee project builds on the biopharma company’s efforts to increase its U.S. footprint, where it has already spent more than $3 billion, and will focus on producing plasma-derived therapies.

KING OF PRUSSIA, Pa., Aug. 3, 2021 /PRNewswire/ -- CSL Behring, a global biotherapeutics leader received U.S. Food and Drug Administration (FDA) approval for its supplemental request (submitted Aug.

The Pennsylvania biotech company CSL Behring says it is on track to file for approval of its hemophilia B gene therapy by the end of June after releasing pivotal data showing statistical superiority ...